Skip to main content
|

Add a bookmark to get started

Bookmarks info
Catherine Huang

Catherine Huang

Associate
San Diego
About

Dr. Cathy Huang represents clients in patent litigation in both United States district courts and the ITC. Her clients include multinational life sciences corporations, including in the medical devices space, as well as global consumer electronics providers. Cathy has also externed for the Honorable Michael M. Anello in the U.S. District Court for the Southern District of California.

Prior to law, Cathy received her Ph.D. in Molecular and Cellular biology from Baylor College of Medicine in Houston, Texas, where she studied the signaling effects of cancer pharmaceuticals using novel 3D platforms and biotechnologies. Before joining DLA Piper, Cathy worked in the Intellectual Property department at Life Technologies (now Thermo Fisher Scientific). She has also served as an expert witness in a criminal matter, and she has industry experience bringing emerging biomedical technologies to market.

Areas of FocusLife SciencesIntellectual PropertyPatent Litigation
Bar admissionsCalifornia
Education
  • J.D., University of San Diego 2014

    Order of Barristers

  • Ph.D., Molecular and Cellular Biology, Baylor College of Medicine 2010
  • B.A., Biological Sciences, University of Texas at Austin 2003

Awards

  • CALI Award, IP Seminar:  “Gene Patents:  Why Patent Eligibility Was Always a Legal Fiction”
  • Susan G. Komen for the Cure research grant
  • Abbott Pharmaceuticals Scholarship
  • Summer Medical Research and Training Program at Baylor College of Medicine

Bylines

  • Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. 1 Integrin Mediates an Alternative Survival Pathway in Breast Cancer Cells Resistant to Lapatinib. Breast Cancer Res. 2011 Aug. 31; 13(4): R(84).
  • Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6): 1351-61.
  • Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2): 583-93.

Memberships And Affiliations

  • Member, DLA Piper Associate Advisory Council

Connect

Phone

+1 619 699 2744
(Work, San Diego)
CallvCardLinkedInPrint
SitemapPrivacy policyYour privacy choicesLegal noticesCookie policyMake a payment

DLA Piper is global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA piper's structure, please refer the Legal Notices page of this website. All rights reserved. Attorney advertising.

© 2023 DLA Piper US